In situ programming of leukaemia-specific T cells using synthetic DNA nanocarriers.

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Nature Nanotechnology

• Publication date

  2017-04-17

• Fields of study

  Biology, Medicine, Computer Science

• Identifiers
  DOI 10.1038/nnano.2017.57PMID 28416815PMCID PMC5646367
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Enhanced CAR T-cell engineering using non-viral Sleeping Beauty transposition from minicircle vectors

  2017cited by this paper
• Phase I trials using Sleeping Beauty to generate CD19-specific CAR T cells.

  2016cited by this paper
• Nanoparticle-mediated transcriptional modification enhances neuronal differentiation of human neural stem cells following transplantation in rat brain.

  2016cited by this paper
• Gene Therapy: The View from NCATS

  2016cited by this paper
• Immunotherapy of acute leukemia by chimeric antigen receptor-modified lymphocytes using an improved Sleeping Beauty transposon platform

  2016cited by this paper
• Synthesis and application of poly(ethylene glycol)-co-poly(β-amino ester) copolymers for small cell lung cancer gene therapy.

  2016cited by this paper
• Adoptive cell transfer as personalized immunotherapy for human cancer

  2015cited by this paper
• CAR therapy: the CD19 paradigm.

  2015cited by this paper
• Minicircle DNA vectors for gene therapy: advances and applications

  2015cited by this paper
• Large-scale Clinical-grade Retroviral Vector Production in a Fixed-Bed Bioreactor

  2015cited by this paper
• Rational development and characterization of humanized anti–EGFR variant III chimeric antigen receptor T cells for glioblastoma

  2015cited by this paper
• Polymeric Nanoparticles for Nonviral Gene Therapy Extend Brain Tumor Survival in Vivo

  2015cited by this paper
• Synthetic biology approaches to engineer T cells.

  2015cited by this paper
• CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia.

  2015cited by this paper
• A Novel Chimeric Antigen Receptor Against Prostate Stem Cell Antigen Mediates Tumor Destruction in a Humanized Mouse Model of Pancreatic Cancer

  2014cited by this paper
• Identification of six new susceptibility loci for invasive epithelial ovarian cancer

  2014cited by this paper
• Chimeric antigen receptor T cells for sustained remissions in leukemia.

  2014cited by this paper
• Tumour heterogeneity and cancer cell plasticity

  2013cited by this paper
• Chimeric antigen receptor-modified T cells for acute lymphoid leukemia.

  2013cited by this paper
• Evaluation of Long-term Transgene Expression in piggyBac-Modified Human T Lymphocytes

  2013cited by this paper
• CD19 CAR-Targeted T Cells Induce Long-Term Remission and B Cell Aplasia in an Immunocompetent Mouse Model of B Cell Acute Lymphoblastic Leukemia

  2013cited by this paper
• Mimicking cellular transport mechanism in stem cells through endosomal escape of new peptide-coated quantum dots

  2013cited by this paper
• A Hyperactive Transposase Promotes Persistent Gene Transfer of a piggyBac DNA Transposon

  2012cited by this paper
• Cell transfer immunotherapy for metastatic solid cancer—what clinicians need to know

  2011cited by this paper
• The expression of exogenous genes in macrophages: obstacles and opportunities.

  2009cited by this paper
• Monitoring the Efficacy of Adoptively Transferred Prostate Cancer–Targeted Human T Lymphocytes with PET and Bioluminescence Imaging

  2008cited by this paper
• Targeted elimination of prostate cancer by genetically directed human T lymphocytes.

  2005cited by this paper
• Specific transgene expression in human and mouse CD4+ cells using lentiviral vectors with regulatory sequences from the CD4 gene.

  2003cited by this paper
• An improved flow cytometric assay for the determination of cytotoxic T lymphocyte activity.

  2002cited by this paper
• Therapeutic haemoglobin synthesis in beta-thalassaemic mice expressing lentivirus-encoded human beta-globin.

  2000cited by this paper
• Therapeutic haemoglobin synthesis in β-thalassaemic mice expressing lentivirus-encoded human β-globin

  2000cited by this paper
• An enhancer that directs lineage-specific expression of CD8 in positively selected thymocytes and mature T cells.

  1997cited by this paper

• Current state of CAR-T cell therapies for solid tumors.

  2026cites this paper
• Unleashing CAR-T potential in solid tumors: overcoming intrinsic and extrinsic hurdles to improve therapy

  2026cites this paper
• Achievements, challenges, and perspectives in the design of boron delivery agents for neutron capture therapy

  2026cites this paper
• Next generation CAR-T cells to tackle down solid tumors.

  2026cites this paper
• In Vivo CAR-T Therapies-A New Era of Programmable Immunity.

  2026cites this paper
• Emerging strategies to reduce the side effects of CAR-T cell therapy: focusing on gene editing and nanotechnology.

  2026cites this paper
• Synergizing Artificial Intelligence with In Vivo CAR-T Cell Generation: A New Paradigm for Democratized Immunotherapy.

  2026cites this paper
• Optimizing In Vivo CAR-T Cell Engineering for Cancer Immunotherapy.

  2026cites this paper
• Polyanion Chemistry Engineers Ternary RNA Nanoparticle Structure/Function from the Inside-Out

  2026cites this paper
• Overcoming challenges in CAR‐T therapy for malignancies: Mechanisms and strategies

  2026cites this paper
• In vivo engineering of CAR-T cells: delivery strategies and clinical translation

  2026cites this paper
• Toward In Vivo CAR T Cell Therapy: Perfecting CAR and Lipid Nanoparticle Design.

  2026cites this paper
• CD3ɛ Nanobody-Engineered Extracellular Vesicles Driving In Vivo Generation of BiTE-Secreting CAR-Ts for Solid Tumor Therapy With Memory Response and Minimal Immunogenicity.

  2026cites this paper
• Advances in immune cell-based therapeutic agents for the treatment of inflammation-related diseases

  2026cites this paper
• Toward precision immunotherapy: In vivo gene editing of T, NK, and myeloid cells.

  2026cites this paper
• Nanoparticles-enhanced CAR-T cell therapy: current advances and future directions.

  2026cites this paper
• Deterministic droplet-based co-encapsulation of single cells through inertial and hydrodynamic focusing.

  2026cites this paper
• In vivo engineering of murine T cells using the evolved adeno-associated virus variant Ark313.

  2025cites this paper
• Enhanced Pulmonary and Splenic mRNA Delivery Using DOTAP-Incorporated Poly(β-Amino Ester)-Lipid Nanoparticles.

  2025cites this paper
• Expanding the horizon of CAR T cell therapy: from cancer treatment to autoimmune diseases and beyond

  2025cites this paper
• Nanomaterials in gene therapy and genome editing: challenges and emerging directions

  2025cites this paper
• From bench to body: In vivo CAR engineering in the clinic

  2025cites this paper
• Advances in Clinical Trials of Boron Neutron Capture Therapy

  2025cites this paper
• In vivo CAR-T cell therapy and its technologies: A perspective

  2025cites this paper
• Engineering Nanoparticles to Modulate Extracellular Matrix and Immune Components of the Tumor Microenvironment in Cancer Immunotherapy

  2025cites this paper
• Poly(beta-amino esters): applications in immunology

  2025cites this paper
• From ex vivo to in vivo chimeric antigen T cells manufacturing: new horizons for CAR T-cell based therapy

  2025cites this paper
• Hybrid Nanocarriers for Cancer Therapy: Advancements in Co-Delivery of Gene Therapy and Immunotherapy

  2025cites this paper
• Present and future of cancer nano-immunotherapy: opportunities, obstacles and challenges

  2025cites this paper
• Chimeric Antigen Receptor Cells Solid Tumor Immunotherapy Assisted by Biomaterials Tools.

  2025cites this paper
• An inherent T cell-activating mRNA delivery platform for in vivo CAR T generation

  2025cites this paper
• Integrating CAR-T cells with other immunotherapies for improved efficacy in cancer patients.

  2025cites this paper
• Advancing Cancer Immunotherapy Using Lipid Nanoparticle-Based Approaches

  2025cites this paper
• Nanotechnology for CAR T cells and tumour-infiltrating lymphocyte therapies

  2025influential citation
• Under the Hood: Evidence-Based Review of Allogeneic Chimeric Antigen Receptor T Cells for Hematologic Malignancies.

  2025cites this paper
• Tracing the development of CAR-T cell design: from concept to next-generation platforms

  2025cites this paper
• Applications of nanoparticles in CAR-T cell therapy: non-viral manufacturing, enhancing in vivo function, and in vivo generation of CAR-T cells

  2025influential citation
• Nanotechnology-enhanced immunotherapies for pancreatic ductal adenocarcinoma: challenges and opportunities

  2025cites this paper
• Synergically enhanced anti-tumor immunity of in vivo panCAR by circRNA vaccine boosting

  2025cites this paper
• Nanotechnology for immuno-oncology

  2025cites this paper
• A New Approach to In Vivo Transformation of Killer T cells.

  2025cites this paper
• Lipid nanoparticles: a promising tool for nucleic acid delivery in cancer immunotherapy

  2025cites this paper
• Prediction of high-performing spleen-targeted lipid nanoparticles using a deep learning model for robust anticancer immunotherapy.

  2025cites this paper
• In vivo CAR-T cell therapy: New breakthroughs for cell-based tumor immunotherapy

  2025cites this paper
• In vivo chimeric antigen receptor (CAR)-T cell therapy

  2025cites this paper
• Azobenzene-integrated photoresponsive DNA with universal design principles and cross-disciplinary applications: A review.

  2025cites this paper
• T Cell-Targeting Nanotherapies for Atherosclerosis.

  2025cites this paper
• Engineered Biomarkers for Point‐of‐Care Diagnostics

  2025cites this paper
• In vivo CAR cell therapy: from bench to bedside

  2025cites this paper
• Genetically Encoded DNA Origami for CAR-T-Based Immunotherapy.

  2025cites this paper
• Lymph Node‐Targeted Nanomaterials for Controlled Nano‐Immunotherapy

  2025cites this paper
• In Situ Chimeric Antigen Receptor Macrophage Therapy via Co-Delivery of mRNA and Immunostimulant.

  2025cites this paper
• Pioneering biomimetic biomaterial for leukemia therapy enhancement: a review

  2025cites this paper
• Breakthrough for Anticancer Immunotherapy: Current Advances in Manufacturing Protocols of Chimeric Antigen Receptor-Based Therapies

  2025cites this paper
• The progress and perspective of nanomedicine in modulating the tumor immune microenvironment

  2025cites this paper
• Efficient gene delivery to immune cells via a recombinant multifunctional chimeric peptide nanocarrier: Implications in immunotherapy.

  2025cites this paper
• AND-gated protease-activated nanosensors for programmable detection of anti-tumour immunity

  2025cites this paper
• Tuning Surface Valences of Nanoengagers to Enhance Their Structural Advantages for Efficiently Redirecting T Cells against Solid Tumors.

  2025cites this paper
• Nanomedicine in Cancer Therapeutics: Current Perspectives from Bench to Bedside

  2025cites this paper
• Interrogation of the Tumor Microenvironment by Nanoparticles.

  2025cites this paper
• Technologies for chimeric antigen receptor transgene delivery.

  2025cites this paper
• Nanomedicine in Immunotherapy for Non‐Small Cell Lung Cancer: Applications and Perspectives

  2025cites this paper
• Recent Advances in mRNA Delivery Systems for Cancer Therapy

  2025cites this paper
• Interfacial T cell engineering

  2025cites this paper
• Neuroimmune interactions: The bridge between inflammatory bowel disease and the gut microbiota

  2025cites this paper
• Chimeric Antigen Receptor (CAR) T-cell Therapy: Engineering Immune Cells To Treat Liver Diseases.

  2025cites this paper
• State of the art in CAR-based therapy: In vivo CAR production as a revolution in cell-based cancer treatment

  2025influential citation
• CAR T cell therapies in gastrointestinal cancers: current clinical trials and strategies to overcome challenges

  2025cites this paper
• Unveiling Cellular Responses and Underlying Immune Effects Induced by Boron Neutron Capture Therapy.

  2025cites this paper
• Legumain In Situ Engineering Promotes Efferocytosis of CAR Macrophage to Treat Cardiac Fibrosis

  2025cites this paper
• From Multi‐Omics to Visualization and Beyond: Bridging Micro and Macro Insights in CAR‐T Cell Therapy

  2025cites this paper
• High‐Efficiency Ocular Delivery of Brain‐Derived Neurotrophic Factor and Oligomycin for Neuroprotection in Glaucoma

  2025cites this paper
• In vivo CAR engineering for immunotherapy

  2025cites this paper
• Advancing cancer gene therapy: the emerging role of nanoparticle delivery systems

  2025influential citation
• Polymer-Based DNA Delivery Nanoplatforms for Chimeric Antigen Receptor T Cells Engineering.

  2025cites this paper
• Material-Driven Therapeutics: Functional Nanomaterial Design Paradigms Revolutionizing Osteosarcoma Treatment

  2025cites this paper
• An overview on in-vivo generation of CAR-T cells using CRISPR-loaded functionalized nanocarriers for treating B-cell lineage acute lymphoblastic leukemia

  2025cites this paper
• A bibliometric analysis of challenges and advancements in the integrated application of nanoparticles and chimeric antigen receptor T cell therapy

  2025cites this paper
• Targeted in vivo delivery of genetic medicines utilizing an engineered lentiviral vector platform results in CAR T and NK cell generation

  2025cites this paper
• CAR-T therapy-based innovations in the enhancement of contemporary anti-tumor therapies

  2025cites this paper
• Nanomaterials Trigger Functional Anti‐Tumoral Responses in Primary Human Immune Cells

  2025cites this paper
• T cell-specific non-viral DNA delivery and in vivo CAR-T generation using targeted lipid nanoparticles

  2025cites this paper
• Innovative strategies for improving CAR-T cell therapy: A nanomedicine perspective

  2025cites this paper
• Research progress on chimeric antigen receptor-based immunotherapy against autoimmune diseases

  2025cites this paper
• Co-delivery of TRAIL DNA and salinomycin for cancer therapy via enhanced apoptosis and cancer stemness inhibition.

  2025cites this paper
• Lung metastasis and recurrence is mitigated by CAR macrophages, in-situ-generated from mRNA delivered by small extracellular vesicles

  2025cites this paper
• Organoid-driven nanomedicine platform development.

  2025cites this paper
• Nanocarrier‐Based Systems for Targeted Delivery: Current Challenges and Future Directions

  2025cites this paper
• Harnessing mRNA-lipid nanoparticles as innovative therapies for autoimmune diseases

  2025cites this paper
• Smart CAR-T Nanosymbionts: archetypes and proto-models

  2025cites this paper
• Revolution in Cell Therapy: In Vivo Chimeric-Antigen-Receptor-T-Cell Therapy Breakthroughs and Promises for the Future

  2025cites this paper
• Glyco-nanomaterials as a therapeutic target in drug delivery and biomedicine: A review.

  2025cites this paper
• Advances in nanomaterial-based therapeutic research for spinal cord injuries: an overview

  2025cites this paper
• Nanotechnology Meets the Tumor Microenvironment: Unlocking New Horizons in Cancer Therapy.

  2025cites this paper
• A review of application of nanotechnology in tumor therapy

  2025cites this paper
• Genome-edited allogeneic CAR-T cells: the next generation of cancer immunotherapies

  2025cites this paper
• In vivo nano-engineering T cells for CAR-T therapy.

  2025cites this paper
• Nanoparticle-based strategy in CAR-T cell immunotherapy: challenges, implications, and perspectives

  2025cites this paper
• In vivo CAR-T cell engineering: concept, research progress, potential challenges and enhancement strategies

  2025cites this paper
• Advances in strategies to improve the immunotherapeutic efficacy of chimeric antigen receptor-T cell therapy for lymphoma

  2025cites this paper